AURA Form 4 reports sale transactions

de los Pinos Elisabet reported open-market sale transactions in a Form 4 filing for AURA.

Rhea-AI Filing Summary

de los Pinos Elisabet reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 47,648 shares at a weighted average price of $5.06 per share. Following the reported transactions, holdings were 409,815 shares.

Insider Trade Summary

Net Seller: 47,648 shares

Net Sell 2 txns

Insider de los Pinos Elisabet

Role See Remarks

Sold 47,648 shs ($241K)

Type	Security	Shares	Price	Value
Sale	Common Stock	47,648	$5.06	$241K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 409,815 shares (Direct); Common Stock — 127,763 shares (Indirect, By EdIP Revocable Trust)

Footnotes (3)

1. F1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
2. F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.04 to $5.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Aura Biosciences (AURA) report?

Aura Biosciences reported an insider tax-related sale by Elisabet de los Pinos of 47,648 common shares. The sale occurred on February 17, 2026, in automatic transactions linked to restricted stock unit vesting, rather than discretionary open-market selling for portfolio management.

Why did Elisabet de los Pinos sell Aura Biosciences shares?

The shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units. According to the disclosure, these sales were automatic and not at her discretion, meaning they were triggered by tax requirements rather than an elective sale decision.

At what price were the Aura Biosciences shares sold in this Form 4?

The reported weighted average sale price was $5.06 per share. The filing notes the shares were sold in multiple transactions within a price range of $5.04 to $5.26, and detailed trade information is available to investors or regulators upon request from the reporting person.

How many Aura Biosciences shares does the insider hold after this sale?

Following the tax-related sale, Elisabet de los Pinos held 409,815 Aura Biosciences common shares directly. She also had indirect ownership of 127,763 shares through the Elisabet de los Pinos Revocable Trust, reflecting a substantial remaining equity position associated with her role at the company.

How are indirect Aura Biosciences holdings reported for this insider?

Indirect holdings are reported as shares owned by the Elisabet de los Pinos Revocable Trust dated April 8, 2016. The Form 4 states she is a trustee of this trust, so those 127,763 shares are shown as indirectly owned, separate from her directly held 409,815 shares of common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 07:46 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

de los Pinos Elisabet

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MA 02135

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		S(1)		47,648	D	$5.06(2)	409,815	D
Common Stock								127,763	I	By EdIP Revocable Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.04 to $5.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.

Remarks:

President and Chief Executive Officer

	/s/ Conor Kilroy, as Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.